Rhumbline Advisers Has $406,000 Stake in Paratek Pharmaceuticals Inc (PRTK)

Rhumbline Advisers decreased its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 19.2% during the fourth quarter, Holdings Channel reports. The fund owned 22,665 shares of the specialty pharmaceutical company’s stock after selling 5,396 shares during the period. Rhumbline Advisers’ holdings in Paratek Pharmaceuticals were worth $406,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Cadence Capital Management LLC increased its holdings in shares of Paratek Pharmaceuticals by 101.2% during the 4th quarter. Cadence Capital Management LLC now owns 49,328 shares of the specialty pharmaceutical company’s stock valued at $883,000 after acquiring an additional 24,806 shares during the last quarter. Moody Aldrich Partners LLC boosted its stake in Paratek Pharmaceuticals by 26.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 54,394 shares of the specialty pharmaceutical company’s stock valued at $974,000 after purchasing an additional 11,324 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Paratek Pharmaceuticals by 12.4% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 92,366 shares of the specialty pharmaceutical company’s stock valued at $1,654,000 after purchasing an additional 10,202 shares during the period. Iguana Healthcare Management LLC bought a new stake in Paratek Pharmaceuticals during the 3rd quarter valued at approximately $879,000. Finally, Belpointe Asset Management LLC bought a new stake in Paratek Pharmaceuticals during the 3rd quarter valued at approximately $228,000. 74.44% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of PRTK stock opened at $13.05 on Friday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.72. Paratek Pharmaceuticals Inc has a 12 month low of $11.85 and a 12 month high of $29.00. The company has a market capitalization of $418.19, a price-to-earnings ratio of -3.95 and a beta of 0.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.03). Paratek Pharmaceuticals had a negative return on equity of 93.16% and a negative net margin of 706.00%. The firm had revenue of $5.07 million during the quarter, compared to the consensus estimate of $5.00 million. equities research analysts forecast that Paratek Pharmaceuticals Inc will post -3.44 EPS for the current year.

In other Paratek Pharmaceuticals news, COO Evan Loh sold 3,040 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total value of $43,228.80. Following the completion of the sale, the chief operating officer now owns 144,870 shares in the company, valued at approximately $2,060,051.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert S. Radie sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total value of $42,660.00. Following the completion of the sale, the director now owns 9,330 shares of the company’s stock, valued at approximately $132,672.60. The disclosure for this sale can be found here. Insiders sold a total of 40,664 shares of company stock valued at $573,226 in the last quarter. Corporate insiders own 4.90% of the company’s stock.

PRTK has been the subject of several recent analyst reports. ValuEngine downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. HC Wainwright increased their target price on Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, March 2nd. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Tuesday, January 23rd. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Finally, UBS downgraded Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Paratek Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $40.00.

ILLEGAL ACTIVITY NOTICE: “Rhumbline Advisers Has $406,000 Stake in Paratek Pharmaceuticals Inc (PRTK)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3337725/rhumbline-advisers-has-406000-stake-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Capital One Financial Weighs in on Cousins Properties’ Q3 2018 Earnings
Royal Gold  Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Royal Gold Forecasted to Post Q3 2018 Earnings of $0.42 Per Share
Campbell Soup  Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Campbell Soup Forecasted to Post Q3 2018 Earnings of $0.60 Per Share
Infineon Technologies  PT Set at €28.00 by Goldman Sachs
Infineon Technologies PT Set at €28.00 by Goldman Sachs
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Hauck & Aufhaeuser Reiterates €16.50 Price Target for Hamburger Hafen und Logistik
Drägerwerk  Earns “Neutral” Rating from Deutsche Bank
Drägerwerk Earns “Neutral” Rating from Deutsche Bank


Leave a Reply

© 2006-2018 Ticker Report. Google+.